Related Experiment Video
Updated: Jun 30, 2025
One Minute, Sub-One-Watt Photothermal Tumor Ablation Using Porphysomes, Intrinsic Multifunctional Nanovesicles
Published on: September 17, 2013
"Four-in-One" Nanozyme for Amplified Catalytic-Photothermal Therapy
Qing Zhang1, Tinglong Zhuang2, Xiaohuan Sun1
1School of Chemistry and Chemical Engineering, Yangzhou University, Yangzhou 225002, China.
Abstract:
The cancer therapeutic efficacy of the peroxidase (POD)-mimicking nanozyme-based monotherapy is significantly hindered due to insufficient intratumoral hydrogen peroxide (H2O2) and glutathione (GSH) consumption effect on reactive oxygen species (ROS). In this study, we present the development of poly(o-phenylenediamine)@gold nanoparticles (AuNPs) (PoPD@Au) nanocomposites for multifunctional catalytic-photothermal therapy. These nanocomposites exhibit triple distinct nanozymatic activities, i.e., POD-like activity that catalyzes H2O2 to ROS, glucose oxidase (GOx)-like activity that supplements endogenous H2O2, and GSH depleting activity that decreases the ROS consumption efficiency. This open source and reduce expenditure strategy for ROS generation allows for the amplification of tumor oxidative stress, thereby enhancing anti-tumor efficiency. Additionally, the PoPD@Au nanocomposites demonstrate outstanding photothermal conversion efficiency, contributing to the synergistic effect between PoPD and AuNPs. Moreover, we reveal the improved photothermal performance of PoPD@Au triggered by the tumor microenvironment pH, which provides additional benefits for targeted catalytic-photothermal therapy. This "four-in-one" design of PoPD@Au enables efficient anti-tumor effects both in vitro and in vivo, making it a universal strategy for engineering catalytic-photothermal therapeutic nanoagents.
Insights
This study developed poly(o-phenylenediamine)@gold nanoparticles (PoPD@Au) for cancer therapy. These nanocomposites enhance tumor oxidative stress and photothermal effects for improved anti-tumor efficiency in vitro and in vivo.
Area of Science:
- Nanotechnology
- Biomedical Engineering
- Materials Science
Background:
- Cancer monotherapy efficacy is limited by low intratumoral hydrogen peroxide (H2O2) and high glutathione (GSH) levels, which reduce reactive oxygen species (ROS) effectiveness.
- Nanozyme-based therapies require strategies to overcome these limitations for enhanced anti-tumor outcomes.
Purpose of the Study:
- To develop poly(o-phenylenediamine)@gold nanoparticles (PoPD@Au) nanocomposites for multifunctional catalytic-photothermal cancer therapy.
- To engineer a "four-in-one" nanoagent with enhanced ROS generation and photothermal conversion for improved anti-tumor efficacy.
Main Methods:
- Synthesized PoPD@Au nanocomposites exhibiting peroxidase-like, glucose oxidase-like, and GSH-depleting activities.
- Investigated the nanocomposites' ability to catalyze H2O2 to ROS, supplement endogenous H2O2, and reduce ROS consumption by GSH.
- Evaluated the photothermal conversion efficiency and pH-triggered performance of PoPD@Au for targeted therapy.
Main Results:
- PoPD@Au nanocomposites demonstrated triple nanozymatic activities, amplifying tumor oxidative stress.
- Enhanced ROS generation and GSH depletion were observed, leading to increased anti-tumor efficiency.
- The nanocomposites exhibited outstanding photothermal conversion efficiency, with pH-dependent performance, showing significant anti-tumor effects both in vitro and in vivo.
Conclusions:
- The "four-in-one" PoPD@Au nanocomposites offer a universal strategy for engineering effective catalytic-photothermal therapeutic nanoagents.
- This approach overcomes limitations in traditional nanozyme-based cancer monotherapy by enhancing ROS generation and photothermal conversion.
- The developed nanoagent shows significant promise for advanced cancer treatment with improved therapeutic outcomes.
More Related Videos
11:20An Integrated System to Remotely Trigger Intracellular Signal Transduction by Upconversion Nanoparticle-mediated Kinase Photoactivation
Published on: August 30, 2017
09:45Photodynamic Therapy with Blended Conducting Polymer/Fullerene Nanoparticle Photosensitizers
Published on: October 28, 2015